The PALLAS-reactor is the successor to the Hoge Flux Reactor (High Flux Reactor or HFR). Early 2004, the current owner of the HFR, the Nuclear Research Group (NRG) initiated PALLAS with a group of companies and research institutes, namely Mallinckrodt Medical (currently Curium), Reactor Institute Delft (part of TU Delft), and the European Institute for Energy and Transport (JRC-IET). NRG was involved in the initiative as project manager. NRG then went to work on the further elaboration and implementation of the project and set up a dedicated project team in 2009.
The high age of research reactors across the globe increases the risk of unplanned halts to production. This led to a global shortage of medical isotopes from 2007-2011. In order to secure the supply of medical isotopes on a global scale, the Dutch government decided to replace the Hoge Flux Reactor. The Ministry of Economics and the Province of Noord-Holland granted PALLAS 80 million euros in the form of a loan to finance the first risky phase.
With the establishment of the Foundation Preparation Pallas-reactor (December 16, 2013) the PALLAS project was incorporated in an independent entity. The Foundation is responsible for the successful completion of the first phase of the project: the design, tendering, and licensing procedure. The Foundation is also responsible for attracting funding for the second phase: the construction and commissioning.
Read the statutes (in Dutch) of the Foundation.